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Background: Congenital generalized lipodystrophy (CGL) or Berardinelli–Seip congenital lipodystrophy (BSCL) is a
rare genetic syndrome characterized by the absence of adipose tissue. As CGL is thought to be related to
malfunctions in adipocyte development, genes involved in the mechanisms of adipocyte biology and maintenance
or differentiation of adipocytes, especially transcription factors are candidates. Several genes (BSCL1-4) were found
to be associated to the syndrome but not all CGL patients carry mutations in these genes.
Methods and results: In a patient with CGL and insulin resistance we investigated the known candidate genes but
the patient did not carry a relevant mutation. Analyses of the insulin activated signal transduction pathways in
isolated fibroblasts of the patient revealed a postreceptor defect altering expression of the immediate early gene
c-fos. Sequence analyses revealed a novel homozygous point mutation (c.–439, T→A) in the patients’ c-fos
promoter. The point mutation was located upstream of the well characterized promoter elements in a region with
no homology to any known cis-elements. The identified mutation was not detected in a total of n=319 non
lipodystrophic probands. In vitro analyses revealed that the mutation facilitates the formation of a novel and specific
protein/DNA complex. Using mass spectrometry we identified the proteins of this novel complex. Cellular
investigations demonstrate that the wild type c-fos promoter can reconstitute the signaling defect in the patient,
excluding further upstream signaling alterations, and vice versa the investigations with the c-fos promoter
containing the identified mutation generally reduce basal and inducible c-fos transcription activity. As a
consequence of the identified point mutation gene expression including c-Fos targeted genes is significantly
altered, shown exemplified in cells of the patient.
Conclusion: The immediate-early gene c-fos is one essential transcription factor to initiate adipocyte differentiation.
According to the role of c-fos in adipocyte differentiation our findings of a mutation that initiates a repression
mechanism at c-fos promoter features the hypothesis that diminished c-fos expression might play a role in CGL by
interfering with adipocyte development.
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Lipodystrophy can be acquired or inherited and results
in partially or complete loss of adipose tissue. In the
most severe form, congenital generalized lipodystrophy
(CGL) or Berardinelli–Seip congenital lipodystrophy
(BSCL), total absence of adipose tissue is associated with* Correspondence: d.mueller-wieland@asklepios.com
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reproduction in any medium, provided the oraltered development, fatty liver, muscular hypertrophy,
hypertriglyceridemia, acanthosis nigricans, hyperinsulin-
ism and type-2-diabetes [1,2].
CGL is rare with estimated 1:10 million births and
thought to be a genetic syndrome with autosomal reces-
sive trait [2]. In humans several candidate genes (BSCL1-
4) were found to be associated to the syndrome [1,3].
BSCL1/AGPAT2 and BSCL2/seipin are identified in the
majority of CGL patients. In single families BSCL3/
caveolin-1 and BSCL4/PTRF-Cavin were identified. The
BSCL genes are part of mechanisms involved in the adipo-
cyte formation and growth including lipid droplet for-Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thesis [1]. Thus CGL have been valuable models for the
identification of new genetic loci involved in development,
distribution and plasticity of white fat cells. Although pa-
tients are rare and an estimated 1 of 4 existing cases has
been included into studies, not all individuals identified
bare mutations in these target genes [1].
Lipodystrophy resemble syndromes of disturbed adipo-
cyte biology or metabolism but the severe congenital
forms are thought to be related to malfunctions in adipo-
cyte development [4,5]. Therefore genes involved in the
differentiation of adipocytes, especially transcription fac-
tors, are hot candidates. Prominent examples are PPARγ,
SREBP-1c in HIV therapy and SREBP-1c or C/EBP in
mouse models causing lipodystrophy [2,4-8]. Another po-
tential candidate is the transcription factor c-Fos a mem-
ber of the AP-1 complex that is essential to initiate
adipocyte differentiation. Accompanied with peak c-fos
gene expression a sequential gene expression cascade of
specific transcription factors necessary in adipocyte devel-
opment is temporarily initiated leading to fully differenti-
ated adipocytes [9,10]. C-fos has been proven to be
essential in this transcriptional activation and knockdown
of c-fos abolished the ongoing differentiation process [10].
Since a mutation in the known BSCL genes have not
been found a patient with CGL and insulin resistance we
examined insulin signaling as central metabolic signal
transduction pathways and show the identification of a
homozygous point mutation in the c-fos promoter
(c.–439, T→A) in this patient. This mutation causes a
novel protein/DNA complex which ubiquitously lowers
basal and inducible c-fos promoter activity. According to
the role of c-fos in adipocyte differentiation our investi-
gations provoke the hypothesis that diminished c-fos ex-
pression interferes with adipocyte development and
might play a role in CGL.
Methods
Cell culture
Fibroblasts initiated from skin biopsies of patient and
healthy caucasian volunteer controls were expanded for 4
cycles and stored in liquid nitrogen. Cells were recultured
(DMEM, 10% FCS; Life Technologies, Darmstadt,
Germany) and expanded for a maximum of 3 passages be-
fore harvesting. For exogenous stimulation fibroblasts
were grown to 70% confluence and serum starved (1%
FCS) for 40 h (quiescent fibroblasts indicated as basal in
figure legends) prior to induction with 10-7 M insulin, 10-8
M IGF-1, 1.5×10-8 EGF or 3.3×10-9 M PDGF. Preadi-
pocytes (3T3-L1) and muscle cells (A7r5) were cultured in
DMEM and liver cells (HepG2) in RPMI 1640 (Life Tech-
nologies) supplemented with 10% FCS. Institutional re-
search ethics approval (PV3641) in line with the Helsinki
Declaration was obtained for this study.Nuclear extracts
Nuclear extracts from fibroblasts of the patient and con-
trols, or HepG2 cells were prepared as described [11].
Insulin induced signal transduction
MAPK activity assays and western blotting with polyclonal
anti-Akt or anti-phospho Akt antibody (New England
Biolabs, Frankfurt, Germany) or polyclonal anti-MAPK
antibody (BD Transduction; Heidelberg, Germany) were
performed as described [11].
Real-time (RT) PCR
Total RNA was extracted with RNeasy Mini Spin Kit
(Qiagen, Hilden, Germany). RT- PCR analyses were
performed in triplicates with c-fos gene-specific probes
and 18S RNA internal standard (Applied Biosystems,
Darmstadt, Germany) as described [12]. Expression results
were determined as relative RNA amounts of target.
Plasmid constructs for transient transfection of primary
fibroblasts
C-fos promoter (nt −734 to +43; numbering based on
TS (=1) according to K00650) was PCR amplified from
genomic DNA of controls and patient using following
primers: -734 to −712: 5’-GCGAGGAACAGTGCTAGT
ATTGCT-3’/ +43 to +12: 5’-CGGCTCAGTCTTGGCTT
CTCAGTTGCTCGCT-3’. Wild type c-fos promoter
fragment and the corresponding fragment of the patient
were inserted in sense orientation into pGL3basic vector
(Promega, Mannheim, Germany) to bring the reporter
gene luciferase under control of wild type c-fos pro-
moter (pc-fos-wt) or the mutated promoter (pc-fos -
439T>A). The expression vector pFA-Elk-1 containing
the regulative domains of transcription factor Elk-1 (aa
307 to 427) fused to the heterologous DNA binding do-
mains of Gal4 (aa 1 to 147) under control of a MLV-
promoter was used (Life Technologies). For monitoring
transactivation the reporter plasmid pGal4-Luc5 con-
taining the luciferase gene under control of 5× Gal4
binding elements was cotransfected in these experiments
(Life Technologies). As reference of transfection effi-
ciency the β-galactosidase expression vector pEF-ßGal
was used. Independent plasmid preparations and cells
were used for replicate experiments.
Transfection
Cell suspensions (2×105 cells/well) of 3T3-L1, A7r5,
HepG2 cells or fibroblasts of patient and control were
mixed with vectors as indicated in figure legends and
pulsed for 18 msec (3T3-L1, A7r5, HepG2) or 9 msec
(fibroblasts). For exogenous induction, cells were serum-
starved on day one following transfection for 40 h and in-
cubated with 10-7M insulin or 3.3×10-9M PDGF for 3 h
before harvesting. Transfection, monitoring of transfection
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described [11].
Direct sequence analyses
Genomic DNA was extracted from fibroblasts of patient
or control using the Qiagen blood kit™. For reevaluation of
the identified mutation only limited amounts of genomic
DNA of the patient’s parents but no biopsies were avail-
able. The coding sequence of AGPAT2 (NM_006412.3),
caveolin-1 (NM_001753.4; NM_001172895.1), seipin
(NM_001122955.3), CAV/PTFR (NM_012232) and c-fos
promoter (K00650) were analyzed by direct sequencing
(ABI PRISM 3100, Applied Biosystems).
Restriction analyses for the identified c-fos promoter
mutation
Genomic DNA of 319 unrelated caucasian subjects was
isolated from PMBCs and c-fos promoter (−603 to +12)
was amplified (−603 to −579: 5’ primer: 5’-AGG
CTTAAGTCCTCGGGGTCCTGT-3’; +43 to +12: 3’ primer:
5’-CGGCTCAGTCTTGGCTTCTCAGTTGCTCGCT-3’).
PCR products were reamplified with a mutated primer
(−441: C>A) introducing a Tsp509I restriction site solely in
wild type c-fos promoter (5’ primer: -470 to −440, c-fos
mut −441: C>A: 5’-CATTGAACCAGGTGCGAATGTT
CTCTCTAA-3‘ and 3‘ primer −337 to −307: 5’-AGATG
TCCTAATATGGACATCCTGTGTAAG-3’). PCR products
were Tsp509I digested and size fractionated. Genomic DNA
of patient was always treated in parallel for control. 10% of
samples were randomly chosen to confirm results by direct
sequencing.
DNaseI protection analyses
Footprinting analyses were performed using the sure
track footprinting kit™ (GE Healthcare, Munich,
Germany). Promoter fragments (nt −462 to −325) were
isolated from pc-fos-wt or pc-fos-patient by EcoRI/
EcoNI restriction and cohesive ends were labeled with
20 μCi [α32P] dATP and Klenow fragment. 100.000 cpm
of radiolabeled fragments were incubated with increas-
ing concentrations of nuclear extracts (4 μg, 8 μg, 20 μg,
40 μg) from human liver cells (HepG2) and subsequently
digested for 1 min with different concentrations of
DNaseI (0.11U, 0.33U, 1.0U). Reactions were terminated
and deproteinized by LiCl precipitation. DNA fragments
were precipitated and separated on an 8% PAGE
containing 7 M urea. Purine nucleotide sequence ladders
from the EcoRI/EcoNI promoter fragments were loaded
in parallel to confirm sequence of protected areas.
Electrophoretic mobility shift assay (EMSA)
EMSA were performed according to [13] and reactions
were analyzed on 5% non-denaturating PAGE. For ana-
lyses of the in vitro ternary complex formation withnuclear extracts of fibroblasts from control or the pa-




AGGTGCCC) were labeled with 20 μCi [α32P]dGTP
using 5U Klenow fragment, prior to use. For com-
pletion experiments 100- or 10-fold molar excess of
unlabeled sre fragments or unspecific SP-1 promoter
fragment (5’-GTTAGGGGCGGGATGGGCGGAGTT -3’)
were used.
Analyses of the novel protein/DNA interaction at the
c-fos promoter were performed with c-fos-wt (−451
to −431: 5’-TGTTCTCTCTCATTCTGCGCCG-3’) or c-
fos-patient (−451 to −431, -439T>A: 5’-TGTTCTCTCT
CAATCTGCGCCG-3’) endlabeled with 5U PNK and 20
μCi [γ32P]dATP, prior to use. For competition experi-
ments 10× or 100× unlabeled c-fos-wt or pc-fos-patient
fragment were used. Experiments were performed with
nuclear extracts (5 μg) of human liver cells (HepG2).
Protein identification of protein/DNA complex proteins by
MALDI-MS
For preparative EMSA a Cy3-labeled c-fos-patient frag-
ment was used in the procedure. Gels were scanned
using a Typhoon scanner (GE, Freiburg, Germany) and
fluorescence marked bands were cut from gels. The gel
slices were placed on a 10% SDS-PAGE for separation of
complex proteins. Four independent EMSA replicates
were performed and cutted protein/DNA complex were
separated on four SDS-PAGE each. Of all protein bands
three different punch samples were excised and
subjected to mass spectrometry analyses according to
[14] for identification. Acquired mass spectra (peptide
mass fingerprint) were automatically calibrated and an-
notated using Compass 1.3 software and xml formatted
peak lists were transferred to Proteinscape3.0 (Bruker
Daltonik, Bremen Germany). MS peptide mass fingerprint
were used to search a human sub-set of Swiss-Prot
(Sprot_2011; 20249 20401 protein entries) non-redundant
database using Mascot search engine (Version 2.2, Matrix
Science Ltd, London, UK) Mass tolerance was set to 50
ppm for peptide spectra and a combined mascot score
over 70 was taken significant (p < 0.01). For verifying the
results each protein spot was picked and identified from at
least three physically different gels.
Affymetrix chip expression analyses: identification of
differentially regulated transcripts independent to
individual expression variation
Fibroblasts of patient and 6 individual controls were cul-
tured to passage 6 each. Four replicate analyses of pa-
tient cells (initiated from two primary stored cell pools)
and 6 individual controls (initiated from one primary
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RNA were processed according to the GeneChip One-Cycle
eukaryotic Target Labeling Assay (GeneChip Expression
analysis technical Manual, http://www.affymetrix.com/
support/Technical/manual/expression_manual.affx) and used
for expression analyses with Hu95A_v2 Arrays (Affymetrix
UK Ltd). Syntheses of cRNA and fragmentation were quality
controlled and monitored with a RNA 6000 nano kit
(Agilent, Taufkirchen, Germany). Detection of probe sets
was performed using a GeneChip scanner (GCOS 1.4 pack-
age, Affymetrix). The original CEL files were directly
implemented into Genespring 12.0 (Agilent) for analyses.Figure 1 Localization of the postreceptor defect to c-fos expression. A
B) Phosphorylation of MAPK was assayed by western blot analyses. Activity
ternary complex at sre element of c-fos promoter in control and patient. Th
competition; competition: 2: 100x SRE, 3: 10x SRE, 4: 100x SP-1, 5: 10x SP-1)
PDGF stimulation in patient and control cells. Results are given as means (±
mRNA. The mRNA levels were normalized against 18S rRNA as internal con
each performed in triplicate. *p< 0.05 vs basal control.The Genespring 12.0 Volcano Plot analyses workflow with
default settings (paired t-test, multiple testing correction:
Benjamini-Hochberg) of the gene expression data sets were
used to identify genes with statistic significant expression
(p < 0.05) and a minimum 1.5-fold difference among condi-
tions. Full data sets are available under accession number
GSE39825 (www.ncbi.nlm.nih.gov/geo/).
Web based functional annotation of differentially
expressed genes and identified proteins
For functional annotation and conserved promoter
element site search web based tools were used) Western blot analyses of Akt phosphorylation and abundance.
of MAPK was detected in in-gel kinase assays. C) Formation of the
e specific complex is indicated by an arrow (lane F: free probe, 1: no
. D) Activation of ternary complex factor Elk-1 following insulin and
S.D.). *p< 0.05 vs basal control. E) Transcriptional activation of c-fos
trol. Values are means (±S.D.) from four independent experiments,
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annotation protein IDs or Affymetrix IDs, fold
change, and t-test p-value of detection significance
were imported to Ingenuity Pathway Analysis (IPA)
System (http://www.ingenuity.com). IPA was carried
out with p < 0.002 as cutoff point. Pathways indicat-
ing altered transcriptional regulation were deduced
from fold change differences observed.
Statistical analyses
Data are given as means ± S.D. Students t-test was used
to determine statistical significance.
Results
Patient characteristic and genetics
The female caucasian patient was born at term with re-
duced birth weight (2,950 g). The parents were healthy,
not consanguineous and gave birth to four further
healthy children. At age of one year the patient retrieved
to thrive and beginning lipodystrophy was diagnosed.
Pronounced acanthosis nigricans was observed, being a
hint for altered insulin signaling. Until the age of five
years prediabetes, progressive hepatomegaly and lipoa-
trophy appeared with complete loss of adipose tissue.
Physical examination revealed generalized decreased
subcutaneous adipose tissue, distended abdomen with
enlarged palpable liver and growth retardation from 10%
(1 year) to 75% (7 years) of normal range. The patient
had the typical appearance of congenital generalizedFigure 2 Identification and impact of a homozygous c-fos promoter p
c-fos promoter (T→ A) at position c.-439 was identified in the patient. B) T
C) in a restriction based assay with 319 control subjects. Representative samlipodystrophy including hypertrichiosis, hepatomegaly,
splenomegaly, but no mental retardation. The patient
had marked muscularity probably due to missing sub-
cutaneous adipose tissue. The main known candidate
genes associated with congenital generalized lipodys-
trophy, i.e. BSCL1/AGPAT2, BSCL2/seipin, BSCL3/
caveolin-1 and BSCL4/PRTF were analyzed. No se-
quence alteration specific for the lipodystrophic pheno-
type was identified (data not shown). At age of five years
laboratory analyses showed elevated plasma cholesterol
levels (450 mg/dl) and modestly elevated triglycerides
(218 mg/dl). Glucose intolerance detected by oGTT
showed an increase of blood glucose levels from 103
mg/dl (normal range 65 to 100 mg/dl) up to 176 mg/dl
(normal range 80 to 126 mg/dl) and plasma insulin
levels from 96 mU/l to 276 mU/l, respectively, indicating
insulin resistance. The patient died at the age of eight
during a hyper acute varicella infection as primary cause
of death. An autopsy was not performed.
Insulin mediated transcriptionally activation of the c-fos gene
As the patient was the only known case of lipodystrophy
in the family nothing remained but analyzing a possible
defect in insulin signaling, we characterized known sig-
naling pathways. For this purpose we utilized primary fi-
broblasts initiated from skin biopsies.
The in vitro insulin receptor binding capacity, auto-
and substrate-phosphorylation was in normal range
(data not shown). The insulin mediated signalingoint mutation in the patient. A) A homozygous point mutation in
he mutation was not identified in the patient’s father or mother or
ples are shown (lane 1–5; p: patient; M: size standard).
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(Figure 1A) and ERK1/2-MAPK activation or activity
(Figure 1B) was comparable to controls in patient cells,
indicating no disturbance in these pathways. A definite
endpoint of MAPK cascades is the transcriptional activa-
tion of the immediate-early genes c-fos [17], whereas theFigure 3 Identification and characterization of a novel protein/DNA c
patient. A) Protein binding to c-fos promoter and mapping of nucleotides
pc-fos-c.–439 T→A DNA fragments were subjected to DNaseI protection as
(HepG2) nuclear protein extracts and digested with varying DNaseI concen
occur with c-fos–c.-439T>A. The sequence of protected areas P1 (nt −413 t
and P3 (nt −458 to −455 (GTGC) indicated the mutation being located in P
sequence ladder). B) EMSA with nuclear protein extracts from liver cells (He
probe. The specific complex is indicated by an arrow. Mutation specific com
of non radiolabeled fragments of either c-fos-wt or pc-fos-c.–439 T→A (lan
competitor, 4: 100x cross competition) C) Size fractionation of EMSA protei
subjected to mass spectrometry. Acquired data from each individual spot w
protein entries) for protein identification.c-fos gene activity is directly related to formation of a
ternary transcription activation complex at the sre-element
and the phosphorylation of the ternary complex fac-
tor Elk-1 by ERK1/2-MAPK [18]. Investigations showed
that the formation of the ternary complex (Figure 1C)
and Elk-1-activation dependent transcription was notomplex forming specifically at the mutation identified in the
necessary for complex formation. Radiolabeled c-fos-wt or mutated
say with increasing amounts (◄: 4 μg, 8 μg, 20 μg, 40 μg) of liver cells
trations (◄: 0.11U, 0.33U to 1.0U). A protein/DNA interaction does solely
o −403 (CCCAGCCGCGG) P2 (nt −441 to −428 (CAATCTGCGCCGTT)
2. A typical result from 5 experiments is shown (lane GA: purine
pG2) using c-fos-wt (−451 to −430) or mutated pc-fos-c.–439 T→A as
plex formation was tested by cross competition with 100-fold excess
e F. free probe, 1: no competition; competition: 2: 50x, 3: 100x specific
n band on denaturing SDS PAGE. All resulting protein bands were
ere used to search a human sub-set of Swiss-Prot (Sprot_2011; 20249
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in patient cells induction of c-fos mRNA expression was
nearly completely lost following insulin and IGF-1 in-
duction and clearly reduced following PDGF and EGF
induction in contrast to control cells (Figure 1E). These
findings focused the defect to c-fos gene directly.
Identification of a point mutation in c-fos promoter
causing a novel specific protein/DNA interaction
Sequence analyses of the patients’ c-fos gene identified next
to a common heterozygous SNP in 5’UTR (rs7101; c.–60) a
novel homozygous point mutation in the promoter at pos-
ition c.–439 (Figure 2A) upstream of well characterized
regulatory promoter elements. This mutation was not iden-
tified in 319 control subjects or in the confirmed parents of
the patient, indicating a de novo mutation (Figure 2B).
One functional possibility of a point mutation in a
promoter is the direct interference with protein/DNA
interactions. Utilizing the c-fos promoter in nuclease
protection assays revealed novel protein binding sites
(P1-P3) only with DNA-fragments bearing the identified
point mutation in P2 (Figure 3A). EMSA confirmed that
this specific protein/DNA interaction only occurs if the
point mutation was present (Figure 3B). A mass spec-
trometry approach revealed that the novel formed pro-
tein/DNA complex consisted of at least 13 proteinsTable 1 Functional annotation of proteins identified in the no
Category Term EASE
GOTERM_MF Nucleotide binding 2.20
GOTERM_MF RNA binding 1.80
GOTERM_MF Structure-specific DNA binding 2.10
GOTERM_MF ATP binding 6.00
GOTERM_MF Adenyl ribonucleotide binding 6.40
GOTERM_MF Adenyl nucleotide binding 8.50
GOTERM_MF Ribonucleotide binding 1.90
GOTERM_MF Purine nucleotide binding 2.40
GOTERM_MF ATP-dependent helicase activity 3.00
GOTERM_MF Purine NTP-dependent helicase activity 3.00
GOTERM_MF Double-stranded telomeric DNA binding 4.20
GOTERM_MF Protein C-terminus binding 6.00
GOTERM_MF Sequence-specific DNA binding 1.30
GOTERM_MF ATP-dependent DNA helicase activity 2.10
GOTERM_MF Single-stranded RNA binding 2.30
GOTERM_MF ATPase activity 3.10
GOTERM_MF DNA helicase activity 3.30
GOTERM_MF Single-stranded DNA binding 4.60
GOTERM_MF DNA-dependent ATPase activity 4.70
GOTERM_MF Promoter binding 4.70
GOTERM_MF Double-stranded DNA binding 7.90
For functional annotation of proteins identified and listed in Figure 3C web based t
were classified according to their molecular function given in the column “term”. Th
EASE (upper bound of the distribution of Jacknife Fisher exact probabilities). Fold e(Figure 3C). Database analyses showed that identified
proteins were not classical transcription factors, but nu-
cleases, helicases or structural proteins (Table 1).
The point mutation c.–439 T→A in the 5’UTR of c-fos gene
results in ubiquitous impairment of c-fos promoter activity
To test the regulatory relevance of identified mutation in
the c-fos promoter we performed promoter reporter gene
analyses. Transfecting a wild type c-fos promoter into the
patient’s cells revealed that the basal and inducible pro-
moter activity is completely reconstituted (Figure 4A). Vice
versa transfecting a c-fos promoter bearing the identified
mutation into control cells revealed that the observed
diminished expression and inducibility of c-fos was
dependent from cellular environment (Figure 4A). These
data exclude further proximal signaling defects and support
a defect intrinsic to the c-fos promoter as the mutation
identified. Further analyses demonstrated that this observa-
tion was not cell specific as in preadipocytes, muscle and
liver cells c-fos promoter activity and activation was evenly
inhibited by the point mutation (Figure 4B-D).
Biological relevance of reduced basal and inducible c-fos
expression
To test if the mutation and novel protein/DNA complex
observed has an impact in cellular context, we performedvel DNA binding complex
Score Benjamini Fisher exact Fold enrichment
E-07 6.80E-06 4.10E-08 5.3
E-04 3.70E-03 1.90E-05 9
E-04 3.30E-03 6.90E-06 29.8
E-04 7.40E-03 1.10E-04 5.1
E-04 6.60E-03 1.30E-04 5.1
E-04 7.50E-03 1.70E-04 4.8
E-03 1.20E-02 4.60E-04 4.1
E-03 1.40E-02 6.10E-04 3.9
E-03 1.50E-02 8.70E-05 33.1
E-03 1.50E-02 8.70E-05 33.1
E-03 1.90E-02 7.80E-06 432.8
E-03 2.30E-02 2.60E-04 23
E-02 4.50E-02 1.70E-03 7.1
E-02 7.00E-02 2.30E-04 86.6
E-02 6.90E-02 2.70E-04 80.1
E-02 8.90E-02 3.10E-03 9.7
E-02 9.10E-02 6.00E-04 54.1
E-02 1.20E-01 1.10E-03 39.3
E-02 1.20E-01 1.20E-03 38
E-02 1.20E-01 1.20E-03 38
E-02 1.90E-01 3.50E-03 22.3
ools as http://david.abcc.ncifcrf.gov/ were used. Within these analyses proteins
e data sets were analyzed with the categorical over-representation function of
nrichment indicates the enrichment of term in search string.
Figure 4 Effect of the identified homozygous c-fos promoter point mutation on c-fos transcription. A) Basal and inducible c-fos promoter
activity is dependent on wt c-fos promoter and abrogated by mutated c-fos promoter (pc-fos-c.–439 T→A) in patient and control cells. Data of
replicate promoter reporter analyses (n=6) are given as mean (±S.D.; p< 0.05). General transcriptional impairment due to c-fos promoter (pc-fos-
c.–439 T→A) mutation in B) preadipocytes (3T3L1), C) muscle cells (A7r5) and D) liver cells (HepG2). Data of promoter reporter analyses are given
as mean of replicate experiments (n=6) (±S.D; p<0.05).
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Table S1). Functional analyses of these results revealed
that multiple metabolic or transcriptional processes and a
large fraction of genes involved in cell cycle control and
differentiation were affected (Additional file 2: Table S2).
Data base analyses suggest that most of differentially regu-
lated transcripts bear the c-fos responsive AP-1 promoter
consensus sequence (Figure 5A). Further in silico analyses
indicate that next to c-fos and further AP-1 complex fac-
tors, differentially expressed transcripts in the patient are
also regulated by transcription factors necessary in adipo-
cyte differentiation and maturation i.e. ATF4, PPARα,
SREBP-1or-2 and CEBP family members (Figure 5B).
Discussion
Implication of the mutation (c.–439 T→A) in the promoter
of c-fos gene
Congenital lipodystrophy is characterized by the com-
plete loss of adipose tissue. In our patient with CGL weidentified a homozygous de novo point mutation in the
c-fos promoter. Although this is an unexpected finding,
increasing genomic information indicated that approxi-
mately 50–100 germ line de novo mutations can occur
in each individual [19]. Nevertheless, the mutation iden-
tified in this study has a clear functional relevance of c-
fos promoter activity. Due to the identified mutation a
novel mutation-specific protein/DNA interaction is
formed. As consequence basal and inducible c-fos ex-
pression is ubiquitously lowered. The proteins identified
in the complex represent no classical DNA interacting
proteins but DNA modifying helicases, nuclear ribonu-
cleoproteins (hnRP), structural proteins, and heat shock
proteins. It was shown that the single strand binding
ATP dependent helicases are involved in telomere main-
tenance, double strand breaking repair and DNA unwind-
ing as needed to transcriptional activation, especially it
has long been noted that UV initiated DNA damage inter-
feres with inducibility of c-fos expression and UV induced
Figure 5 Gene expression alterations due to diminished c-fos expression. A) Gene expression date were analyzed for statistically significant
different gene expression (1.5-fold difference; p<0.05). Resulting transcript IDs were subjected to automated annotation for conserved AP-1
transcription factor binding sites. B) The pathways showing altered transcriptional regulation were deduced from differential gene expression
identified. Colored genes (red and green) were identified differentially regulated by microarray analysis. Genes directly regulated by c-fos are
indicated (blue line). Predicted transcription factors (white) involved in observed gene regulation were deduced using Ingenuity Pathway Analysis
((IPA System (http://www.ingenuity.com).
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[20,21]. HnRPs localized to the nucleus are involved in
transcriptional repression processes including c-fos
mRNA transcription [22]. Furthermore nuclear actin or
nucleolin are involved in chromatin-remodeling processes
and actin can be associated to hnRNPs A/B type family as
also shown here [23,24]. Such modifications in chromatin
structure are required for gene expression and adipocyte
differentiation as local chromatin remodeling has been de-
scribed in the regulation of the PPARγ transcription dur-
ing adipocyte differentiation [25,26].
All together the novel protein complex seems to act on
c-fos promoter as ubiquitous transcriptional repressor.
Mechanistically one can speculate that the complex alters
DNA packaging, masks basal or activating promoterelements or interacts with transcription factors. The novel
protein DNA complex identified might constitutively
mimic a transcriptional repression process that usually is
under tight regulation in cells [27].
The consequence of lowering c-fos expression is a dif-
ferential gene expression pattern in our patient com-
pared to controls. Further analyses shows that the
reduced c-fos expression affects genes involved in mul-
tiple metabolic pathways, transcriptional control and a
large fraction of genes involved in cell cycle control and
differentiation processes most of them AP-1 dependent.
Of special note are genes involved in adipocyte differenti-
ation as Wnt5A, IL6, FGF-2, ODC-1, C/EBP, NR2F2,
INHBB, SFRP1 or ITGA6. On the other hand gene func-
tional annotation revealed that genes differentially expressed
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scription factors as C/EBPs, PPARs or the SREBP family.
Can the reduced c-fos promoter activity be related to CGL?
On cellular level the point mutation identified in our pa-
tient and the binding of the novel protein complex re-
sults in reduced basal as well as inducible c-fos
expression but not complete loss of c-fos expression.
This reduced c-fos expression influences expression on
many other genes. This might be due to the fact that c-
Fos doesn’t act as single transcription factor but is part
of AP-1 complex. This protein complex consists of a
combination of two proteins from various homologues
proteins of Jun, ATF, MAF and Fos families, i.e. c-jun,
JUNB, JUND, ATF2, ATF3/LRF1, B-ATF, JDP1, JDP2, c-
Maf, MafB, MafA, MafG/F/K, Nrl, c-fos, Fra-1, Fra-2,
FOSL or FosB. As consequence depending on dimer
composition the transactivation activity of AP-1 complex
varies from activation to repression of the target gene
transactivation activity [9]. Furthermore, the occupancy
of AP-1 sites by AP-1 transcription complex also influ-
ences transcription of overlapping or adjacent promoter
elements. The direct competition of AP-1 to binding site
CRE or ARE has been reported [27,28]. Knockout mice
deficient for c-Fos revealed phenotypes with severe
osteopetrosis and altered hematopoiesis. They show re-
duced fetal and placental weight, reduced weight gain
and reduced fat mass, but to our knowledge there are no
studies assessing further metabolic parameters [29-31].
However there is a reciprocal interaction between bone
and energy metabolism [32]. Osteoblasts and adipocytes
originate from a common mesenchymal progenitor andFigure 6 Can deminished c-fos transactivation be one cause of adipo
promoter mutation affects signalling by cFos and AP-1 and interferes with
lamininA/C, caveolin, cavin) are included at the levels of functional interactspecific differentiation via BMPs and WNT pathways
determine the cell fate to bone or adipose specific pre-
cursor cells [33]. This speculation is supported by mice
overexpressing Fra-1 which develop lipodystrophy due
to reduced adipocyte differentiation via C/EBPa inhib-
ition and transcriptional repression [34]. Interestingly,
patients with congenital lipodystrophy show increased
bone age and density, enlarged epiphyses, sclerotic skele-
tons and alterations in dentition [35]. Furthermore the
promoter activation of the immediately early gene c-fos
is involved in various signaling cascades. One of those is
IGF-1 signaling, that shares the signaling cascade and
activation mechanisms of c-fos promoter as insulin [11].
As the role of IGF-1 and the GH/IGF-1 axis in various
syndromes with growth restriction is well established
[36] one can speculate that the growth alterations
or skin and hair variations observed in the patient are
most likely a consequence of interference with IGF-1
signaling.
Conclusion
In conclusion we describe the identification of a de novo
point mutation in the promoter of the immediately early
transcription factor c-fos gene which might be associated
with a CGL outcome. We show alteration of the tran-
scription pattern in cells due to reduced c-fos expression
in our patient. Furthermore we suggest a hypothetical
model how reduced c-fos expression potentially inter-
feres with target genes also necessary for differentiation
or maturation of preadipocytes (Figure 6). Our findings
provide evidence for the addition of c-Fos to the list of
genes which might cause congenital lipodystrophy.se tissue malformation? Postulated model how the identyfied c-fos
adipocte differentiation. The BSCL genes (italic; seipin, AGPAT2,
ion in c-fos signalling.
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Additional file 1: Table S1. Summary of differentially regulated
transcripts. Equal amounts of total RNA of patient and 6 individual
controls were used for expression analyses with Hu95A Arrays
(Affymetrix). Expression data analyses utilizing standard algorithmus was
performed with Genespring 12.0 to identify genes with statistic
significant expression (p< 0.05) and a minimum 1.5- fold difference. For
consensus site prediction web based tools as http://david.abcc.ncifcrf.
gov/ were used. (FC: fold change to controls; p= significance of
expression; min; max: minimum and maximum fold change observed in
comparison to controls.
Additional file 2: Table S2. GO annotation of regulated transcripts.
Transcripts are listed in identical order as in Additional file 1: Table S1.
Functional information is given as available. For consensus site prediction
web based tools as http://david.abcc.ncifcrf.gov/ were used.
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